Business
Re: Collaborative Agreement
Re: Collaborative Agreement.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 0902O ValiRx PLC 13 September 2011 \n\n13 September 2011\nValiRx Plc\n(\"ValiRx\" or the \"Company\")\n \nRe: Collaborative Agreement\n \n\"ValiRx to use Physiomics' Virtual Tumour technology \nto accelerate development of promising prostate cancer drug\"\n \n \nValiRx Plc (AIM: VAL), a life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to announce that its wholly-owned subsidiary, ValiPharma Limited, has signed a collaborative agreement (\"Agreement\") with Physiomics plc (AIM: PYC), the Oxford based systems biology company, relating to the further development and accelerated progress of VAL201, ValiPharma's anti-cancer compound.\n \nPhysiomics will use its systems biology expertise and 'Virtual Tumour' proprietary technology to assist ValiRx to accelerate the development of its lead therapeutic, VAL201, and speed its progress through the next stage of VAL201's preclinical programme to support the regulatory requirements prior to its entering clinical trials. \n \nThe Agreement is on a revenue sharing basis, so that Physiomics will not receive a fee for their work, but will receive a percentage of any licensing income received by ValiRx for the compound for use in treating prostate cancer, in due course. The programme will create new IP, which will add value for both parties, with ValiPharma retaining both ownership of all VAL201 associated new IP resulting from the programme and retaining all rights for the commercialisation of VAL201.\n \nPhysiomics' proprietary Virtual TumourTM model is used to simulate cell behaviour in response to new treatments and the results will be used to predict ideal dosing, scheduling and combination treatment regimes to enhance VAL201's potency, for the ideal clinical outcome. The two companies will also collaborate to determine the best regimen to take forward to Phase 1 clinical trials.\n \nThis collaboration follows on from the successful late preclinical studies (announced 28/07/11) into the development of VAL201, which were carried out in collaboration with Oxford University, and which firmly established a potentially important role for VAL201 in treating hormone induced refractory prostate cancer and other conditions of hormone induced uncontrolled cel...